2016 American Transplant Congress
3D-FLM (First, Last, Max): A Novel Summative Measure of Hepatocellular Carcinoma (HCC) Tumor Burden Predicts HCC Recurrence After Liver Transplantation (LT).
1Univ. Colorado, Aurora; 2UCSF, San Francisco.
Risk of recurrent HCC post-LT depends on tumor aggressiveness, pre-LT HCC burden and treatment response while waiting for LT. Standard measures of pre-LT HCC burden…2016 American Transplant Congress
Intraoperative Blood Loss Is a Promoter of Early Tumor Recurrence in Liver Transplant Patients with High Risk Hepatocellular Carcinoma.
Background:Currently, there is an increasing body of evidence that risk of early hepatocellular carcinoma (HCC) relapse following liver transplantation (LT) may be promoted by mechanisms…2016 American Transplant Congress
Comparative Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma (HCC-CCA) Undergoing Liver Transplantation: A Single Center Matched Cohort Analysis.
Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Liver transplant (LT) is the gold standard for hepatocellular carcinoma (HCC) but is contraindicated in known HCC-CCA due to poor prognosis. We compared posttransplant oncologic…2015 American Transplant Congress
Adoptive Immunotherapy With Liver Allograft-Derived NK Cells Improves Recurrence-Free Survival After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Introduction: Previous studies revealed that the recurrence rate of hepatocellular carcinoma (HCC) was still 10–20%, even among liver transplantation (LT) recipients meeting the Milan criteria…2015 American Transplant Congress
Systemic and Local NK and Regulatory Cell Phenotypes and mTori-Induced Tumor-Specific Effector T-Cell Responses Are Key Players Favoring the Development of Squamous Cell Skin Carcinoma Among Kidney Transplant Patients
Renal transplant patients are at higher risk of developing squamous cell carcinoma (SCC). Immunosuppressive agents promote an imbalance between effector and regulatory tumor-specific immune responses,…2015 American Transplant Congress
No Tumor Recurrence After Renal Cell Carcinoma Resected Kidney Transplantation – 5 Year Follow Up
INTRODUCTION:Organ shortage remains the single most significant impediment to increasing low rate of kidney transplantation. One of the strategies to improve it, is a utilisation…2015 American Transplant Congress
Significant Reduction in TRAIL-Expressing NK Cells in Remnant Liver After Partial Hepatectomy Is Strongly Associated With the Impaired Intrahepatic CXCL9–CXCR3 Pathway
Antitumor activity of liver natural killer (NK) cells decreases after partial hepatectomy or liver transplantation (LT), suggesting the susceptibility of patients with depressed immune status…2015 American Transplant Congress
Long-Term Outcome After Liver Transplantation for Unresectable Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment
Background: Liver transplantation remains the only curative treatment option for patients with unresectable hepatocellular carcinoma (HCC). Several bridging treatments are employed because the limited availability…
- « Previous Page
- 1
- …
- 3
- 4
- 5